crt.org
Blood Cancer Resources - MPN Resources | CR&T
http://www.crt.org/Blood-Cancer-and-MPN-Resources
Blood Cancer and MPN Resources. The Silver MPN Center. Edward P. Ambinder, M.D. Morton Coleman, M.D., FACP. John P. Leonard, M.D. Anne Moore, M.D. Malcolm Moore, D.Phil. Mark Pasmantier, M.D. Shahin Rafii, M.D. Andrew I. Schafer, M.D. David A. Scheinberg, M.D., Ph.D. Richard T. Silver, M.D., FACP. Jerry L. Spivak, M.D. Alexander J. Swistel, M.D. Linda T. Vahdat, M.D. Development of Interferon in MPN Therapy. Identification of Mechanism for Resistance to Ibrutinib in Lymphoma. Hall of Fame Event. Ndash; T...
cornellleukemia.com
Myelodysplastic Syndrome | Weill Cornell Leukemia Program
https://cornellleukemia.com/tag/myelodysplastic-syndrome
Weill Cornell Leukemia Program. About the Leukemia Program. Dr Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL. April 13, 2016. Weill Cornell Leukemia Program. Comments Off on Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL. To learn more or see if you are eligible to participate. What to Expect When You’re Expecting MDS. March 10, 2016. Weill Cornell Leukemia Program. Weill Cornell Leukemia Program. March 10, 2016. Comments Of...
cornellleukemia.com
CRUSH!!MDS | Weill Cornell Leukemia Program
https://cornellleukemia.com/crushmds-3
Weill Cornell Leukemia Program. About the Leukemia Program. Tudy, and H. Myelodysplastic syndrome (MDS) is a complicated disease and we do not have a good handle on how to best diagnose and treat it. Doctors and patients need answers as soon as possible and CRUSH! MDS has been designed to speed up the process of getting these answers. MDS is a comprehensive clinical database initiated by Gail J. Roboz, M.D. Director of the Leukemia Program. At Weill Cornell Medicine. Part of the Meyer Cancer Center.
cornellleukemia.com
AML | Weill Cornell Leukemia Program
https://cornellleukemia.com/tag/aml
Weill Cornell Leukemia Program. About the Leukemia Program. Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia. June 3, 2015. Weill Cornell Leukemia Program. Weill Cornell Leukemia Program. Weill Cornell Medical College. Comments Off on Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia. We are pleased t...
cornell-lymphoma.com
Blog | New Developments in Lymphoma | The Lymphoma Program at NewYork-Presbyterian & Weill Cornell Medicine
https://cornell-lymphoma.com/blog
New Developments in Lymphoma. The Lymphoma Program at NewYork-Presbyterian and Weill Cornell Medicine. About the Lymphoma Program. Lymphoma Therapy Approval Timeline. Lymphoma Medicine is Precision Medicine: A Conversation with Dr. John Leonard. August 18, 2016. Last week, Dr. Leonard. Held a lecture to discuss how lymphoma medicine is precision medicine. And dose adjusted R-EPOCH. Around 70% of cases are cured with either of these two treatments, proving that chemotherapy is effective. Lines of therapy&...
cornell-lymphoma.com
New Clinical Trial: Study to Determine the Safety, Pharmacokinetics, & Efficacy of Single Agent CC-122 with Rituximab/Ibrutinib in Patients with Relapsed & Refractory CLL/SLL | New Developments in Lymphoma
https://cornell-lymphoma.com/2015/08/06/new-clinical-trial-study-to-determine-the-safety-pharmacokinetics-efficacy-of-single-agent-cc-122-with-rituximabibrutinib-in-subjects-with-relapsed-refractory-cllsll
New Developments in Lymphoma. The Lymphoma Program at NewYork-Presbyterian and Weill Cornell Medicine. About the Lymphoma Program. Lymphoma Therapy Approval Timeline. Larr; Join Dr. John Leonard for a Twitter Chat hosted by the American Society of Hematology. Research on End of Life Care and the Implication for Lymphoma Patients. New Clinical Trial: Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 with Rituximab/Ibrutinib in Patients with Relapsed and Refractory CLL/SLL.
cornell-lymphoma.com
Hospital Guest Facility | New Developments in Lymphoma
https://cornell-lymphoma.com/hospital-guest-facility
New Developments in Lymphoma. The Lymphoma Program at NewYork-Presbyterian and Weill Cornell Medicine. About the Lymphoma Program. Lymphoma Therapy Approval Timeline. The NewYork-Presbyterian Guest Facility at the Helmsley Medical Tower. Click here to learn more about the NYP Guest Facility. Hospitality for Family and Friends. To learn more about Hospitality for Family and Friends. MAKE A GIFT TO THE LYMPHOMA PROGRAM. Lymphoma Medicine is Precision Medicine: A Conversation with Dr. John Leonard. Physicia...